Be up to date
See our latest update on how we bring cell therapy to the world
Cell therapy is an administration of live cells to the body to treat diseases. It is also highly precise, allowing zeroed-in targeting of afflicted areas. These characteristics make cell therapy not only an excellent way to cover some of the deficiencies modern medicine faces, but also an avenue to develop quality treatments for degenerative diseases and other previously irreversible ailments.
MVC CPC aims to bridge the gap of insufficient cell processing capacity and bring cell therapy to the world.
Medigen Vaccine Biologics Corporation (MVC) is a comprehensive biopharmaceuticals manufacturer whose core competency includes state-of-the-art cell culture technology, PIC/S GMP facility, in-house QA and QC capabilities and experienced teams and consulting experts.
MVC aims to apply these core capabilities and key experiences to our cell processing center (CPC), which envisions to be a regional cell processing CDMO hub providing cell processing, scale up and process optimization services.
MVC develops new vaccines and affordable biosimilars to prevent regional infectious diseases. We aim to become one of the leading pharmaceutical companies for Taiwan and global communities.
Humanity, innovation, and quality are MVC’s core values. Based on the core values, we integrate biomedical technologies and strive to improve human health. We believe that every person, from infants to seniors, can be free from infectious diseases.
Quality Policy Statement
MVC is committed to delivering safe and effective products compliant with regulatory requirements to consumers through continuous improvement of our quality management system.
– MEDIGEN VACCINE BIOLOGICS CORPORATION